MRSN Relative Valuation
MRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRSN is overvalued; if below, it's undervalued.
Historical Valuation
Mersana Therapeutics Inc (MRSN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.47. The fair price of Mersana Therapeutics Inc (MRSN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：27.87
Fair
-2.01
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Mersana Therapeutics Inc. (MRSN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.00. The thresholds are as follows: Strongly Undervalued below -7.13, Undervalued between -7.13 and -4.57, Fairly Valued between 0.56 and -4.57, Overvalued between 0.56 and 3.12, and Strongly Overvalued above 3.12. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.90
EV/EBIT
Mersana Therapeutics Inc. (MRSN) has a current EV/EBIT of -0.90. The 5-year average EV/EBIT is -1.91. The thresholds are as follows: Strongly Undervalued below -7.04, Undervalued between -7.04 and -4.48, Fairly Valued between 0.66 and -4.48, Overvalued between 0.66 and 3.23, and Strongly Overvalued above 3.23. The current Forward EV/EBIT of -0.90 falls within the Historic Trend Line -Fairly Valued range.
9.25
PS
Mersana Therapeutics Inc. (MRSN) has a current PS of 9.25. The 5-year average PS is 2175.12. The thresholds are as follows: Strongly Undervalued below -15527.33, Undervalued between -15527.33 and -6676.11, Fairly Valued between 11026.34 and -6676.11, Overvalued between 11026.34 and 19877.56, and Strongly Overvalued above 19877.56. The current Forward PS of 9.25 falls within the Historic Trend Line -Fairly Valued range.
-1.98
P/OCF
Mersana Therapeutics Inc. (MRSN) has a current P/OCF of -1.98. The 5-year average P/OCF is -4.21. The thresholds are as follows: Strongly Undervalued below -11.10, Undervalued between -11.10 and -7.65, Fairly Valued between -0.77 and -7.65, Overvalued between -0.77 and 2.68, and Strongly Overvalued above 2.68. The current Forward P/OCF of -1.98 falls within the Historic Trend Line -Fairly Valued range.
-1.92
P/FCF
Mersana Therapeutics Inc. (MRSN) has a current P/FCF of -1.92. The 5-year average P/FCF is -4.35. The thresholds are as follows: Strongly Undervalued below -11.03, Undervalued between -11.03 and -7.69, Fairly Valued between -1.01 and -7.69, Overvalued between -1.01 and 2.33, and Strongly Overvalued above 2.33. The current Forward P/FCF of -1.92 falls within the Historic Trend Line -Fairly Valued range.
Mersana Therapeutics Inc (MRSN) has a current Price-to-Book (P/B) ratio of -2.34. Compared to its 3-year average P/B ratio of 23.05 , the current P/B ratio is approximately -110.14% higher. Relative to its 5-year average P/B ratio of 15.55, the current P/B ratio is about -115.04% higher. Mersana Therapeutics Inc (MRSN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -82.49%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -56.60% , the current FCF yield is about -100.00% lower.
-2.31
P/B
Median3y
23.05
Median5y
15.55
-53.42
FCF Yield
Median3y
-82.49
Median5y
-56.60
Competitors Valuation Multiple
The average P/S ratio for MRSN's competitors is 0.00, providing a benchmark for relative valuation. Mersana Therapeutics Inc Corp (MRSN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -12.61%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MRSN decreased by 23.16% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.70 to -1.95.
The secondary factor is the Revenue Growth, contributed -12.61%to the performance.
Overall, the performance of MRSN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Mersana Therapeutics Inc (MRSN) currently overvalued or undervalued?
What is Mersana Therapeutics Inc (MRSN) fair value?
How does MRSN's valuation metrics compare to the industry average?
What is the current P/B ratio for Mersana Therapeutics Inc (MRSN) as of Dec 05 2025?
What is the current FCF Yield for Mersana Therapeutics Inc (MRSN) as of Dec 05 2025?
What is the current Forward P/E ratio for Mersana Therapeutics Inc (MRSN) as of Dec 05 2025?